USA flag logo/image

An Official Website of the United States Government

Combination Therapy of Aspirin and Apyrase for Stroke

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
96484
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
NS071655
Solicitation Year:
N/A
Solicitation Topic Code:
NINDS
Solicitation Number:
N/A
Small Business Information
APT THERAPEUTICS, INC.
4041 Forest Park Avenue SAINT LOUIS, MO -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Combination Therapy of Aspirin and Apyrase for Stroke
Agency: HHS
Contract: 1R43NS071655-01
Award Amount: $287,622.00
 

Abstract:

DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for acute ischemic stroke which is a leading cause of death and disability with almost no effective therapy for most patients. This enzyme strongly inhibits platelet a ctivation and aggregation with modest bleeding risk. We will validate hypothesis that in thromboembolic model of stroke in rats, combination treatment of ASA plus apyrase at acute stage provides more effective protection than ASA or apyrase alone in short term as well as long-term experiments without increasing intracerebral hemorrhage. PUBLIC HEALTH RELEVANCE: We will utilize clinically relevant embolic stroke models in rats to assess neuroprotective effect of aspirin and apyrase treatment.

Principal Investigator:

Ridong Chen
3123398455
RCHEN@APT-THERAPEUTICS.COM

Business Contact:

Ridong Chen
rchen@apt-therapeutics.com
Small Business Information at Submission:

APT THERAPEUTICS, INC.
APT THERAPEUTICS, INC. 4041 Forest Park Avenue SAINT LOUIS, MO 63108

EIN/Tax ID: 143194771
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No